Moderna, Inc. (NASDAQ:MRNA) Director Sells $1,756,200.00 in Stock

Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $117.08, for a total value of $1,756,200.00. Following the completion of the transaction, the director now directly owns 2,269,015 shares in the company, valued at $265,656,276.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Noubar Afeyan also recently made the following trade(s):

• On Wednesday, June 26th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $127.22, for a total transaction of $1,908,300.00.
• On Tuesday, June 11th, Noubar Afeyan sold 202,832 shares of Moderna stock. The shares were sold at an average price of $148.34, for a total transaction of $30,088,098.88.
• On Wednesday, June 5th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $151.25, for a total transaction of $2,268,750.00.
• On Wednesday, May 29th, Noubar Afeyan sold 20,000 shares of Moderna stock. The shares were sold at an average price of $145.08, for a total value of $2,901,600.00.
• On Wednesday, May 22nd, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $157.57, for a total value of $2,363,550.00.
• On Wednesday, May 15th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $127.32, for a total transaction of $1,909,800.00.
• On Wednesday, May 8th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $121.68, for a total transaction of $1,825,200.00.
• On Wednesday, May 1st, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $110.92, for a total transaction of $1,663,800.00.
• On Wednesday, April 24th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $108.32, for a total value of $1,624,800.00.
• On Wednesday, April 17th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $103.38, for a total value of $1,550,700.00.

Moderna Trading Down 1.1 %

MRNA stock opened at $121.46 on Monday. Moderna, Inc. has a twelve month low of $62.55 and a twelve month high of $170.47. The stock has a market capitalization of $46.55 billion, a price-to-earnings ratio of -7.75 and a beta of 1.66. The company has a quick ratio of 3.91, a current ratio of 4.03 and a debt-to-equity ratio of 0.04. The firm’s fifty day simple moving average is $135.29 and its two-hundred day simple moving average is $114.06.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, beating the consensus estimate of ($3.59) by $0.52. The company had revenue of $167.00 million for the quarter, compared to the consensus estimate of $93.26 million. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The firm’s revenue was down 91.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.19 EPS. As a group, analysts anticipate that Moderna, Inc. will post -7.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

MRNA has been the subject of a number of research analyst reports. Canaccord Genuity Group increased their price objective on shares of Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a report on Friday, May 3rd. Piper Sandler reiterated an “overweight” rating and issued a $214.00 price target on shares of Moderna in a report on Thursday, June 27th. Oppenheimer raised their price objective on Moderna from $163.00 to $179.00 and gave the company an “outperform” rating in a research report on Wednesday, June 12th. Evercore ISI reiterated an “in-line” rating and issued a $120.00 target price on shares of Moderna in a research report on Thursday, June 27th. Finally, William Blair restated a “market perform” rating on shares of Moderna in a report on Thursday, June 27th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $134.02.

Institutional Investors Weigh In On Moderna

Hedge funds and other institutional investors have recently modified their holdings of the business. Cedar Wealth Management LLC grew its position in Moderna by 45.0% in the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after acquiring an additional 90 shares during the last quarter. CVA Family Office LLC grew its holdings in shares of Moderna by 21.6% in the second quarter. CVA Family Office LLC now owns 541 shares of the company’s stock worth $64,000 after purchasing an additional 96 shares during the last quarter. Allworth Financial LP increased its stake in Moderna by 6.5% in the 4th quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock worth $165,000 after buying an additional 101 shares during the period. TIAA Trust National Association lifted its holdings in Moderna by 2.3% during the 4th quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock valued at $447,000 after buying an additional 102 shares in the last quarter. Finally, Principle Wealth Partners LLC boosted its position in Moderna by 4.3% in the 1st quarter. Principle Wealth Partners LLC now owns 2,497 shares of the company’s stock valued at $266,000 after buying an additional 102 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.